“The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis”, Reumatismo, vol. 56, no. s1, pp. 74–79, Mar. 2004, doi: 10.4081/reumatismo.2004.1s.74.